<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35598178</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2362</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of clinical investigation</Title><ISOAbbreviation>Eur J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence.</ArticleTitle><Pagination><StartPage>e13818</StartPage><MedlinePgn>e13818</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13818</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/eci.13818</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 infection triggers different auto-antibodies, including anti-apolipoprotein A-1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID-19 and the impact of AAA1 on the inflammatory response and symptoms persistence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All serologies were assessed at one, three, six and twelve months in 193 hospital employees with COVID-19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient-reported COVID-19 symptoms persistence at 12 months. Interferon (IFN)-&#x3b1; and-&#x3b3; production by AAA1-stimulated human monocyte-derived macrophages (HMDM) was assessed in vitro.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID-19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti-SARS-COV2 serologies decreased, but remained significant. From the 3<sup>rd</sup> month on, AAA1 levels predicted persistent respiratory symptoms (area under the curves 0.72-0.74; p&#x2009;&lt;&#x2009;0.001), independently of disease severity, age and gender (adjusted odds ratios 4.81-4.94; p&#xa0;=&#xa0;0.02), while anti-SARS-CoV-2 serologies did not. AAA1 increased IFN-&#x3b1; production by HMDMs (p&#xa0;=&#xa0;0.03), without affecting the IFN-&#x3b3; response.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">COVID-19 induces a marked though transient AAA1 response, independently predicting one-year persistence of respiratory symptoms. By increasing IFN-&#x3b1; response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID-19 risk stratification remains to be determined.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Clinical Investigation published by John Wiley &amp; Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L'Huillier</LastName><ForeName>Arnaud G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-9230-7285</Identifier><AffiliationInfo><Affiliation>Department of Woman, Pediatric Infectious Diseases Unit, Child and Adolescent Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagano</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7075-1182</Identifier><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baggio</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Prison Health, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrey</LastName><ForeName>Diego O</ForeName><Initials>DO</Initials><Identifier Source="ORCID">0000-0003-3247-9274</Identifier><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nehme</LastName><ForeName>Mayssam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Primary Care Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guessous</LastName><ForeName>Idris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Primary Care Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eberhardt</LastName><ForeName>Christiane S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huttner</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posfay-Barbe</LastName><ForeName>Klara M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Woman, Pediatric Infectious Diseases Unit, Child and Adolescent Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerly</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegrist</LastName><ForeName>Claire-Anne</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuilleumier</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>657</GrantID><Agency>De Reuter Foundation</Agency><Country/></Grant><Grant><Agency>Fondation Ancrage</Agency><Country/></Grant><Grant><Agency>Fondation de Bienfaisance du Groupe Pictet</Agency><Country/></Grant><Grant><Agency>Fondation Prive des HUG</Agency><Country/></Grant><Grant><Agency>Geneva University Hospitals and Faculty of Medicine's Center for Vaccinology</Agency><Country/></Grant><Grant><Agency>Geneva University Hospitals and Faculty of Medicine's Centre for Emerging Viral Diseases.</Agency><Country/></Grant><Grant><Agency>Geneva University Hospitals Project and Development Grant</Agency><Country/></Grant><Grant><Agency>Schmidheiny Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Clin Invest</MedlineTA><NlmUniqueID>0245331</NlmUniqueID><ISSNLinking>0014-2972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016632">Apolipoprotein A-I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016632" MajorTopicYN="N">Apolipoprotein A-I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anti-apolipoprotein A-1 autoantibodies</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">symptoms persistence</Keyword><Keyword MajorTopicYN="N">type I interferon response</Keyword></KeywordList><CoiStatement>NV received restricted research grants unrelated to this study from Roche. All the other co&#x2010;authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>22</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35598178</ArticleId><ArticleId IdType="pmc">PMC9348059</ArticleId><ArticleId IdType="doi">10.1111/eci.13818</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:1&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5810582</ArticleId><ArticleId IdType="pubmed">27188830</ArticleId></ArticleIdList></Reference><Reference><Citation>Iseme RA, McEvoy M, Kelly B, et al. A role for autoantibodies in atherogenesis. Cardiovasc Res. 2017;113(10):1102&#x2010;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">28899001</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratton R, Slapak G, Mahungu T, Loes SKD. Autoimmunity and HIV. Current Opinion in Infectious Diseases. 2009;22(1):49&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">19532080</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornaby C, Gibbons L, Mayhew V, Sloan CS, Welling A, Poole BD. B cell epitope spreading: mechanisms and contribution to autoimmune diseases. Immunol Lett. 2015;163(1):56&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">25445494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li SM, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS&#x2010;CoV&#x2010;2 infected patients. Ebiomedicine. 2020;55:102763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng F, Li L, Zeng J, et al. Can we predict the severity of coronavirus disease 2019 with a routine blood test? Pol Arch Intern Med. 2020;130(5):400&#x2010;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">32356642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M, Perricone C, Tonello M, et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS&#x2010;CoV&#x2010;2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol. 2020;38(4):754&#x2010;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">32723434</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A, Slootjes SM, Sellimi A, et al. Immune&#x2010;mediated neurological syndromes in SARS&#x2010;CoV&#x2010;2&#x2010;infected patients. J Neurol. 2020;268(3):751&#x2010;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391231</ArticleId><ArticleId IdType="pubmed">32734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiaffino MT, Natale MD, Garc&#xed;a&#x2010;Mart&#xed;nez E, et al. Immunoserologic detection and diagnostic relevance of cross&#x2010;reactive autoantibodies in coronavirus disease 2019 patients. J Infect Dis. 2020;222(9):1439&#x2010;1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454719</ArticleId><ArticleId IdType="pubmed">32738141</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID&#x2010;19. Ann Rheum Dis. 2020;79(12):1661&#x2010;1663.</Citation><ArticleIdList><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS&#x2010;CoV&#x2010;2. Cell Host Microbe. 2020;27(4):671&#x2010;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142693</ArticleId><ArticleId IdType="pubmed">32183941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D. From anti&#x2010;SARS&#x2010;CoV&#x2010;2 immune responses to COVID&#x2010;19 via molecular mimicry. Antibodies. 2020;9(3):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551747</ArticleId><ArticleId IdType="pubmed">32708525</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M, Wu NC, Zhu XY, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS&#x2010;CoV&#x2010;2 and SARS&#x2010;CoV. Science. 2020;368(6491):630&#x2010;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164391</ArticleId><ArticleId IdType="pubmed">32245784</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrera&#x2010;Soler L, Daguer JP, Barluenga S, et al. Identification of immunodominant linear epitopes from SARS&#x2010;CoV&#x2010;2 patient plasma. Plos One. 2020;15(9):e0238089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480855</ArticleId><ArticleId IdType="pubmed">32903266</ArticleId></ArticleIdList></Reference><Reference><Citation>Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS&#x2010;CoV&#x2010;2 spike protein that elicit neutralising antibodies in COVID&#x2010;19 patients. Nat Commun. 2020;11(1):2806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264175</ArticleId><ArticleId IdType="pubmed">32483236</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID&#x2010;19 patients reveals cross&#x2010;reactivity and correlates of severity. Science. 2020;370(6520):eabd4250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857405</ArticleId><ArticleId IdType="pubmed">32994364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Wu X, Zhang X, et al. SARS&#x2010;CoV&#x2010;2 proteome microarray for mapping COVID&#x2010;19 antibody interactions at amino acid resolution. ACS Cent Sci. 2020;6(12):2238&#x2010;2249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586461</ArticleId><ArticleId IdType="pubmed">33372199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano S, Gaertner H, Cerini F, et al. The human autoantibody response to apolipoprotein A&#x2010;I is focused on the C&#x2010;terminal helix: a new rationale for diagnosis and treatment of cardiovascular disease? Plos One. 2015;10(7):e0132780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503694</ArticleId><ArticleId IdType="pubmed">26177543</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira PC, Ducret A, Ferber P, et al. Definition of human apolipoprotein A&#x2010;I epitopes recognized by autoantibodies present in patients with cardiovascular diseases. J Biol Chem. 2014;289(41):28249&#x2010;28259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192480</ArticleId><ArticleId IdType="pubmed">25170076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano S, Yerly S, Meyer B, et al. SARS&#x2010;CoV2&#x2010; infection as a trigger of humoral response against apolipoprotein A&#x2010;1. Eur J Clin Invest. 2021; 51(11):e13661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420318</ArticleId><ArticleId IdType="pubmed">34324704</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JLC, Pagano S, Virzi J, et al. Autoantibodies to apolipoprotein A&#x2010;1 as independent predictors of cardiovascular mortality in renal transplant recipients. J Clin Med. 2019;8(7):948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679113</ArticleId><ArticleId IdType="pubmed">31261925</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiochos P, Marques&#x2010;Vidal P, Virzi J, et al. Association between anti&#x2010;apolipoprotein A&#x2010;1 antibodies and cardiovascular disease in the general population Results from the CoLaus study. Thromb Haemostasis. 2016;116(4):764&#x2010;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">27384400</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiochos P, Marques&#x2010;Vidal P, Virzi J, et al. Impact of CD14 polymorphisms on anti&#x2010;apolipoprotein A&#x2010;1 IgG&#x2010;related coronary artery disease prediction in the general population. Arterioscl Throm Vas. 2017;37(12):2342&#x2010;2349.</Citation><ArticleIdList><ArticleId IdType="pubmed">29074586</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier N, Pagano S, Combescure C, et al. Non&#x2010;linear relationship between anti&#x2010;apolipoprotein A&#x2010;1 IgGs and cardiovascular outcomes in patients with acute coronary syndromes. Journal of Clinical Medicine. 2019;8(7):1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679072</ArticleId><ArticleId IdType="pubmed">31324073</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier N, Rossier MF, Pagano S, et al. Anti&#x2010;apolipoprotein A&#x2010;1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J. 2010;31(7):815&#x2010;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">20176799</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamsi R. Rogue antibodies could be driving severe COVID&#x2010;19. Nature. 2021;590(7844):29&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33469204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G&#x2010;protein coupled receptors in patients with persistent Long&#x2010;COVID&#x2010;19 symptoms. J Transl Autoimmun. 2021;4:100100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannic T, Satta N, Pagano S, et al. CD14 as a Mediator of the Mineralocorticoid Receptor&#x2010;Dependent Anti&#x2010;apolipoprotein A&#x2010;1 IgG Chronotropic Effect on Cardiomyocytes. Endocrinology. 2015;156(12):4707&#x2010;4719.</Citation><ArticleIdList><ArticleId IdType="pubmed">26393305</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte&#x2010;Macrophage Responses Cause Lethal Pneumonia in SARS&#x2010;CoV&#x2010;Infected Mice. Cell Host Microbe. 2016;19(2):181&#x2010;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752723</ArticleId><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID&#x2010;19 and influenza highlights the role of type I interferons in development of severe COVID&#x2010;19. Sci Immunol. 2020;5(49):eabd1554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402635</ArticleId><ArticleId IdType="pubmed">32651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito B, Broggi A, Pandolfi L, et al. The interferon landscape along the respiratory tract impacts the severity of COVID&#x2010;19. Cell. 2021;184(19):4953&#x2010;4968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373821</ArticleId><ArticleId IdType="pubmed">34492226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Shin EC. The type I interferon response in COVID&#x2010;19: implications for treatment. Nat Rev Immunol. 2020;20(10):585&#x2010;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824445</ArticleId><ArticleId IdType="pubmed">32788708</ArticleId></ArticleIdList></Reference><Reference><Citation>L'Huillier AG, Meyer B, Andrey DO, et al. Antibody persistence in the first 6 months following SARS&#x2010;CoV&#x2010;2 infection among hospital workers: a prospective longitudinal study. Clin Microbiol Infect. 2021;27(5):784.e1&#x2010;784.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816882</ArticleId><ArticleId IdType="pubmed">33482352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridge SH, Pagano S, Jones M, et al. Autoantibody to apolipoprotein A&#x2010;1 in hepatitis C virus infection: a role in atherosclerosis? Hepatol Int. 2018;12(1):17&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814532</ArticleId><ArticleId IdType="pubmed">29423541</ArticleId></ArticleIdList></Reference><Reference><Citation>Satta N, Pagano S, Montecucco F, et al. Anti&#x2010;apolipoprotein A&#x2010;1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. J Infection. 2018;76(2):186&#x2010;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">29198606</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano S, Satta N, Werling D, et al. Anti&#x2010;apolipoprotein A&#x2010;1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J Intern Med. 2012;272(4):344&#x2010;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22329401</ArticleId></ArticleIdList></Reference><Reference><Citation>Preacher KJ, Wichman AL, MacCallum RC, Briggs NE. Latent Growth Curve Modeling. 1st Edition ed. SAGE Publications; 2008.</Citation></Reference><Reference><Citation>Winkler AR, Nocka KH, Sulahian TH, Kobzik L, Williams CM. In vitro modeling of human alveolar macrophage smoke exposure: enhanced inflammation and impaired function. Exp Lung Res. 2008;34(9):599&#x2010;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">19005923</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, et al. Symptoms and functional impairment assessed 8 months after mild COVID&#x2010;19 among health care workers. JAMA. 2021;325(19):2015&#x2010;2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiochos P, Marques&#x2010;Vidal P, Virzi J, et al. Anti&#x2010;apolipoprotein A&#x2010;1 IgG predict All&#x2010;cause mortality and are associated with fc receptor&#x2010;like 3 polymorphisms. Front Immunol. 2017;8:437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394854</ArticleId><ArticleId IdType="pubmed">28458671</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier N, Pagano S, Ludewig B, et al. Anti&#x2010;SARS&#x2010;CoV&#x2010;2 mRNA vaccines as inducers of humoral response against apolipoprotein A&#x2010;1? Eur J Clin Invest. 2022;52(2):e13713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286055</ArticleId><ArticleId IdType="pubmed">34841527</ArticleId></ArticleIdList></Reference><Reference><Citation>Twickler DTM. New insights into Covid&#x2010;19 disease. Apo&#x2010;A1 antibodies are generated after mRNA Covid&#x2010;19 vaccination and after Covid&#x2010;19 infection. Eur J Clin Invest. 2022;52(2):e13729.</Citation><ArticleIdList><ArticleId IdType="pubmed">34921724</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier N, Antiochos P, Marques&#x2010;Vidal P, et al. Prognostic and therapeutic considerations of antibodies against c&#x2010;ter apolipoprotein A&#x2010;1 in the general population. Clin Transl Immunol. 2020;9(12):e1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734471</ArticleId><ArticleId IdType="pubmed">33343896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID&#x2010;19. Nature. 2021;595(7866):283&#x2010;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez&#x2010;Perez AI, Labandeira CM, Pedrosa MA, et al. Autoantibodies against ACE2 and angiotensin type&#x2010;1 receptors increase severity of COVID&#x2010;19. J Autoimmun. 2021;122:102683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193025</ArticleId><ArticleId IdType="pubmed">34144328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy A, Brodsky NN, Sumida TS, et al. Immune dysregulation and autoreactivity correlate with disease severity in SARS&#x2010;CoV&#x2010;2&#x2010;associated multisystem inflammatory syndrome in children. Immunity. 2021;54(5):1083&#x2010;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043654</ArticleId><ArticleId IdType="pubmed">33891889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Orlova E, Sozaeva L, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID&#x2010;19 pneumonia in patients with APS&#x2010;1. J Exp Med. 2021;218(7):e20210554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077172</ArticleId><ArticleId IdType="pubmed">33890986</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV&#x2010;19 Vaccination. N Engl J Med. 2021;384(23):2202&#x2010;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Blagova O, Varionchik N, Zaidenov V, Savina P, Sarkisova N. Anti&#x2010;heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID&#x2010;19. Eur J Immunol. 2021;51(4):893&#x2010;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">33368288</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou Hassan OK, Sheng CC, Wang TKM, Cremer PC. SARS&#x2010;CoV&#x2010;2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications. Curr Cardiol Rep. 2021;23(9):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8330199</ArticleId><ArticleId IdType="pubmed">34342728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for cardiac electrophysiology during the COVID&#x2010;19 pandemic from the heart rhythm society COVID&#x2010;19 task force; electrophysiology section of the american college of cardiology; and the electrocardiography and arrhythmias committee of the council on clinical cardiology. Am Heart Assoc Circ. 2020;141(21):e823&#x2010;e831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243667</ArticleId><ArticleId IdType="pubmed">32228309</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier N, Pagano S, Lahlou K, et al. Head&#x2010;to&#x2010;head comparison of auto&#x2010;antibodies for cardiovascular outcome prediction after myocardial infarction: A prospective study. J Clinic Experiment Cardiol. 2011;23(169). doi:10.4172/2155.9880.1000169</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155.9880.1000169</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>